{"created":"2023-06-19T11:44:13.370702+00:00","id":14071,"links":{},"metadata":{"_buckets":{"deposit":"e9caafd6-fe58-470a-b783-5192eac03694"},"_deposit":{"created_by":16,"id":"14071","owners":[16],"pid":{"revision_id":0,"type":"depid","value":"14071"},"status":"published"},"_oai":{"id":"oai:mie-u.repo.nii.ac.jp:00014071","sets":["334:608:618:1262"]},"author_link":[],"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-03-25","bibliographicIssueDateType":"Issued"}}]},"item_7_date_granted_59":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2021-03-25"}]},"item_7_degree_grantor_57":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_name":"三重大学"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"14101","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_7_degree_name_56":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士(医学)"}]},"item_7_description_14":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Idiopathic pulmonary fibrosis is a chronic, progressive, and lethal lung disease of unknown etiology. Antifibrotic drugs, including pirfenidone, are currently used for the treatment of the disease. The oral administration of pirfenidone is an effective therapy, as demonstrated by several clinical trials, although it causes severe adverse events in some patients. We hypothesized that low-dose intrapulmonary delivery of pirfenidone is effective in human transforming growth factorβ1-driven pulmonary fibrosis. To demonstrate our hypothesis, we compared the therapeutic efficacy of varying doses of pirfenidone administered by oral and intranasal routes in a human transforming growth factorβ1 transgenic mouse with established pulmonary fibrosis. We found similar amelioration of lung cell infiltration, inflammatory and fibrotic cytokines, lung fibrosis score, and hydroxyproline content in mice with human transforming growth factorβ1-mediated pulmonary fibrosis treated with low-dose intranasal pirfenidone and high-dose oral pirfenidone. This study showed that pirfenidone is a potent inhibitor of human transforming growth factorβ1-driven lung fibrosis and that intrapulmonary delivery of low-dose pirfenidone produces therapeutic responses equivalent to high-dose of oral pirfenidone.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_7_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"本文/Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Japan","subitem_description_type":"Other"},{"subitem_description":"13p","subitem_description_type":"Other"}]},"item_7_dissertation_number_60":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"甲医学第2059号"}]},"item_7_publisher_30":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"三重大学"}]},"item_7_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.3389/fphar.2020.593620","subitem_relation_type_select":"DOI"}}]},"item_7_text_31":{"attribute_name":"出版者（ヨミ）","attribute_value_mlt":[{"subitem_text_value":"ミエダイガク"}]},"item_7_text_63":{"attribute_name":"ノート","attribute_value_mlt":[{"subitem_text_value":"Frontiers in Pharmacology 2020; 11: 593620に掲載"}]},"item_7_text_65":{"attribute_name":"資源タイプ（三重大）","attribute_value_mlt":[{"subitem_text_value":"Doctoral Dissertation / 博士論文"}]},"item_7_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Okano, Tomohito","creatorNameLang":"en"},{"creatorName":"オカノ, トモヒト","creatorNameLang":"ja-Kana"},{"creatorName":"岡野, 智仁","creatorNameLang":"ja"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-06-29"}],"displaytype":"detail","filename":"2020DM0328.pdf","filesize":[{"value":"8.2 MB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"label":"2020DM0328","objectType":"fulltext","url":"https://mie-u.repo.nii.ac.jp/record/14071/files/2020DM0328.pdf"},"version_id":"b1106e97-2d6c-45ff-9478-a950e01f3311"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"idiopathic pulmonary fibrosis","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"pirfenidone","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"intrapulmonary delivery","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"oral therapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"adverse effects","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"drug delivery","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis","subitem_title_language":"en"}]},"item_type_id":"7","owner":"16","path":["1262"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-06-29"},"publish_date":"2021-06-29","publish_status":"0","recid":"14071","relation_version_is_last":true,"title":["Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis"],"weko_creator_id":"16","weko_shared_id":-1},"updated":"2023-10-25T04:19:17.631597+00:00"}